Biotech News
Related news
MNKDMannKind2026-10-14 20:01 EST
MannKind to Participate in the Chardan Healthcare Conference
MNKDMannKind2026-11-10 13:00 EST
MannKind to Participate in Upcoming Investor Conferences
SGMTSagimet Biosciences2026-10-29 11:00 EST
Sagimet Biosciences Announces Participation in Upcoming Investor Conference and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
LXRXLexicon Pharmaceuticals2026-11-11 13:30 EST
Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in London
ALGSAligos Therapeutics2026-09-02 12:00 EST
Aligos Therapeutics to Present at the Cantor Global Healthcare Conference
CVRXCVRx2026-07-28 12:30 EST
CVRx to Present at Canaccord Genuity's 46th Annual Growth Conference
VANIVivani Medical2026-07-14 20:03 EST
Vivani Medical to Present at the Emerging Growth Conference on July 15, 2026
NAMSNewAmsterdam Pharma2026-07-01 12:00 EST
NewAmsterdam Pharma Announces Upcoming Presentations at the Alzheimer's Association International Conference (AAIC) 2026
ALTAltimmune2026-11-19 13:00 EST
Altimmune to Participate in the 9th Annual Evercore Healthcare Conference
CVRXCVRx2026-11-17 21:05 EST
CVRx to Participate at the Piper Sandler 38th Annual Healthcare Conference
MannKind
Inhaled Drug Delivery MannKind develops and commercializes drug-device combinations using Technosphere particles and dry-powder inhalers for rapid, deep-lung delivery. Commercial Portfolio Afrezza is an inhaled mealtime insulin, Tyvaso DPI is manufactured for United Therapeutics, and FUROSCIX provides subcutaneous furosemide for fluid...
Recent company news
MNKDMannKind2026-11-10 13:00 EST
MannKind to Participate in Upcoming Investor Conferences
MNKDMannKind2026-11-05 21:01 EST
MannKind Reports Third Quarter 2026 Financial Results and Provides Business Update
MNKDMannKind2026-10-29 20:01 EST
MannKind to Report Third Quarter Financial Results and Host Conference Call on November 5, 2026
MNKDMannKind2026-10-14 20:01 EST
MannKind to Participate in the Chardan Healthcare Conference
MNKDMannKind2026-10-10 00:00 EST
MannKind Data at HFSA 2026 Highlights New Evidence Supporting Furoscix ReadyFlow™ for the Outpatient Management of Edema in Heart Failure (HF) and Chronic Kidney Disease (CKD)
Stock data
- Close
- 3.95 USD
- Market cap
- 1.06B USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States
